IATA’s Guidance for Vaccine and Pharmaceutical Logistics and Distribution provides recommendations for governments and the logistics supply chain to handle the largest and most complex global logistics operation ever undertaken.
Reflecting the complexity of the challenge, the guidance was produced with the support of a broad range of partners, including ICAO, the International Federation of Freight Forwarders Associations (FIATA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pan American Health Organization (PAHO), the UK Civil Aviation Authority, World Bank, the World Customs Organization (WCO) and the World Trade Organization (WTO).
The guidance includes a repository of international standards and guidelines related to the transport of vaccines and will be updated regularly as information is made available to the industry. Accompanying the guidance, IATA established a joint information-sharing forum for stakeholders.
“Delivering billions of doses of a vaccine that must be transported and stored in a deep-frozen state to the entire world efficiently will involve hugely complex logistical challenges across the supply chain,” said IATA’s Director General and CEO, Alexandre de Juniac. “Though the immediate challenge is the implementation of COVID-19 testing measures to re-open borders without quarantine, we must be prepared for when a vaccine is ready. This guidance material is an important part of those preparations.”
Key challenges include the availability of temperature-controlled storage facilities; the roles and responsibilities of all parties involved in the distribution of vaccines; and overall industry preparedness for vaccine distribution.
The industry needs to ensure it has the requisite:
• Capacity and connectivity: The global route network has been reduced dramatically from the pre-COVID 22,000 city pairs. Governments need to re-establish air connectivity to ensure adequate capacity is available for vaccine distribution.
• Facilities and infrastructure: The first vaccine manufacturer to apply for regulatory approval requires the vaccine to be shipped and stored in a deep-frozen state, making ultra-cold chain facilities across the supply chain essential. Some types of refrigerants are classified as a dangerous goods and volumes are regulated which adds an additional layer of complexity.
• Border management: Timely regulatory approvals and storage and clearance by customs and health authorities will be essential. Priorities for border processes include introducing fast-track procedures for overflight and landing permits for operations carrying the COVID-19 vaccine and potential tariff relief to facilitate the movement of the vaccine.
• Security: Vaccines are highly valuable commodities. Arrangements must be in place to ensure that shipments remain secure from tampering and theft. The huge volume of vaccine shipments will require early planning to ensure that existing processes are scalable.